<DOC>
	<DOC>NCT00811642</DOC>
	<brief_summary>The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI</brief_summary>
	<brief_title>Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Participants must be 1870 years male or female Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment. Sign informed consent form Female participants who are pregnant or are nursing. Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B Participants with progressive nervous system diseases( excluding those IFI caused) Participants who take the following drugs known with interference with azole antifungal preparations terfenadine, cisapride, and ebastine within 24 hours before entry astemizole at entry or within 10 days before entry cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry The drugs listed above are prohibited during the investigation Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate &lt;60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities. Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women. Expected to take during investigation or is taking systemic antifungal treatment Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are &gt;2Ã—ULN. Participants expected to survive no more than 72hrs Participants receiving artificial aeration and will not withdraw within 24hrs Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry. Prior enrollment in this study. History of alcohol and/or drug abuse. Participants cannot be compliant in investigator's opinion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>refractory or first line medication intolerable invasive fungal infection</keyword>
</DOC>